15 October 2018
To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.
8 October 2018
We caught up with Shinwon Park at Ewha Womens University to discuss their experiences of updating their longitudinal studies from tablet-only CANTAB Eclipse to the cloud-based CANTAB Connect Research platform.
4 October 2018
A negative, perceptual bias is associated with the onset and maintenance of mood disorders, and is therefore a therapeutic avenue of interest. Here we will discuss the launch of an objective assessment of emotional bias as a potential biomarker of mood.
24 September 2018
We caught up with Adjunct Professor Suvi Rovio to discuss why CANTAB is integral to the success of her large, longitudinal studies into population-based cardiovascular risk.
21 September 2018
What will happen when we eventually develop a treatment that halts the development of early Alzheimer’s disease? Being first-in-class, pharmacovigilance post-marketing will be vitally important to ascertain the long-term effects of the drug: both positive and negative. We need to be prepared for a breakthrough and pre-emptively identify technologies which can find the right patients likely to benefit from the drug and monitor treatment effects in the real world.
18 September 2018
Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes.